* Magenta Therapeutics Inc is expected to show no change in quarterly revenue when it reports results on August 2 (estimated).
*
* Refinitiv's mean analyst estimate for Magenta Therapeutics Inc is for a loss of 19 cents per share.
* The one available analyst rating on the shares is "hold".
* The mean earnings estimate of analysts had fallen by about 24.2% in the last three months.
* Wall Street's median 12-month price target for Magenta Therapeutics Inc is $1, above its last closing price of $0.81.
This summary was machine generated July 31 at 16:00 GMT. All figures in US dollars unless otherwise stated.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments